Although TH with their metabolites and receptor beta have been proposed as therapeutic targets, evidence related to thyroid function in NAFLD/NASH is still controversial; therefore, further studies are necessary to evaluate these interactions and possible therapeutic effects. The gene discussed is TH; the disease is metabolic dysfunction-associated steatohepatitis.